Rocket Pharmaceuticals Inc
RCKTHealthcare|Biotechnology|USA
$3.91
-0.28 (-6.68%)
Tangible Book
$1.59
Earnings Power
$0.30
About
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Stock Price
+23.7%(1Y)
Pipeline Summary
37 total trials9
Phase 1
7
Phase 2
2
Phase 3
2
Phase 4
Recruiting: 10SUSPENDED: 1Unknown: 8Completed: 8ENROLLING_BY_INVITATION: 1Withdrawn: 1NOT_YET_RECRUITING: 2Active: 4Terminated: 2
Active Trials (14)
PKP2-ACM Natural History Study
NCT06644742Cardiomyopathies
Recruiting
Enrollment: 36 participants
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07137338Dilated Cardiomyopathy (DCM)
Phase 1Recruiting
Enrollment: 8 participants
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
NCT06282432Leukocyte Adhesion Deficiency
Active
Enrollment: 9 participants
Danon Disease Natural History Study
NCT06214507Danon Disease
Recruiting
Enrollment: 60 participants
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
NCT04437771Fanconi Anemia Complementation Group A
Active
Enrollment: 9 participants
BioScore
5.4/10
Watchlist
Ownership
Recent Insider Trades
Shah GauravSELL
2026-05-2155,684 shares @ $3.09
Shah GauravSELL
2026-05-192,409 shares @ $3.01
Wilson MartinSELL
2026-05-19662 shares @ $3.01
Militello JohnSELL
2026-05-19384 shares @ $3.01
Wilson MartinSELL
2026-05-133,361 shares @ $3.61
Data last updated: Jul 13, 2026, 12:49 PM